Important Safety Information for Privigen®
Privigen® is indicated for the treatment of patients with primary immunodeficiency (PI) associated with defects in humoral immunity, including but not limited to common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. Privigen® is also indicated to rapidly raise platelet counts to prevent bleeding in patients with chronic immune thrombocytopenic purpura (ITP).
WARNING: Renal dysfunction, acute renal failure, osmotic nephrosis, and death may be associated with the administration of Immune Globulin Intravenous (Human) (IVIg) products in predisposed patients. Administer IVIg products at the minimum infusion rate possible. Renal dysfunction and acute renal failure occur more commonly in patients receiving IVIg products containing sucrose. Privigen® does not contain sucrose. See full Prescribing Information for complete Boxed Warning.
Privigen® is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin, in patients with hyperprolinemia, and in patients with selective IgA deficiency. In patients at risk for developing renal failure, monitor urine output and renal function, including blood urea nitrogen and serum creatinine.
Also monitor patients with risk factors for thrombotic events, including a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, hypercoagulable disorders, prolonged periods of immobilization, and/or known or suspected hyperviscosity.
Aseptic meningitis syndrome (AMS) has been reported infrequently with Privigen® and other IVIg treatments; AMS may occur more frequently with high doses and/or rapid infusion of IVIg. Hemolysis, hemolytic anemia, and pulmonary adverse events have also been reported. There have been reports of noncardiogenic pulmonary edema in patients administered IVIg. If transfusion-related acute lung injury is suspected, test product and patient for antineutrophil antibodies.
Privigen® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
In clinical studies, the most common adverse reactions with Privigen® were headache, pain, nausea, pyrexia/hyperthermia, fatigue, and chills, and anemia. The most serious adverse reactions in chronic ITP patients were aseptic meningitis syndrome in one subject and hemolysis in eight subjects.
Please see full Prescribing Information.
Important Safety Information for Vivaglobin®
Immune Globulin Subcutaneous (Human), Vivaglobin®, is a prescription treatment for patients with primary immunodeficiency (PI).
Immune globulin products, such as Vivaglobin®, should not be taken if you have a history of anaphylactic or severe systemic response to immune globulin (Ig) preparations. If you suspect you are having a severe reaction to Vivaglobin®, discontinue treatment immediately and inform your doctor.
Vivaglobin® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
In clinical trials, the most frequent adverse event was mild or moderate swelling, redness, and itching at the injection site. Other adverse events included headache, gastrointestinal disorder, fever, nausea, sore throat, and rash. No serious reactions were observed, and reactions tended to decrease substantially with repeated use.
If you are receiving Ig therapy for the first time, are new to Vivaglobin®, or have not received Ig therapy within the past eight weeks, your healthcare provider should monitor your initial treatment with Vivaglobin®, as you could experience reactions including fever, chills, nausea, and vomiting. Rarely, these reactions may lead to shock.
Ig administration may impair the effectiveness of virus vaccines, such as measles, mumps and rubella. Consult your doctor if you plan to receive any vaccine.
In clinical studies, Vivaglobin® has been shown to be safe and well tolerated in pediatric patients, without pediatric-specific dose requirements. Safety and effectiveness were not studied in subjects under 2 years of age.
Please see full Prescribing Information and Patient Product Information.
